Evidence map›Paper›PMID 24721393›Full record

ArticleJournal of immunological methods2014

Development of a qPCR method to rapidly assess the function of NKT cells.

Silke Sohn, Irina Tiper, Emily Japp, Wenji Sun, Katherine Tkaczuk, Tonya J Webb

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunological methods, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Identification of Functional Immune Biomarkers in Breast Cancer Patients.International journal of molecular sciences · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Silke SohnDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA.
Irina TiperDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA.
Emily JappDepartment of Medicine, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA.
Wenji SunDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA.
Katherine TkaczukDepartment of Medicine, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA.
Tonya J WebbDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA. Electronic address: twebb@som.umaryland.edu.
University of Maryland, Baltimore · US

Funding

aAPC-Mediated NKT cell Modulation to Enhance Cancer ImmunotherapyK01CA131487 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2008 to 2012
$584k
Restoring NKT cell function: a novel immunotherapeutic strategy for Breast CancerR21CA162273 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$367k
Altered cellular bioenergetics influences NKT cell mediated responses to LymphomaR21CA162277 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$359k
NCI NIH HHS K01 CA131487NCI NIH HHS R21 CA162273NCI NIH HHS R21 CA162277
6 · The paper itself

Abstract

introductionNKT cells comprise a rare, but important subset of T cells which account for ~0.2% of the total circulating T cell population. NKT cells are known to have anti-tumor functions and rapidly produce high levels of cytokines following activation. Several clinical trials have sought to exploit the effector functions of NKT cells. While some studies have shown promise, NKT cells are approximately 50% lower in cancer patients compared to healthy donors of the same age and gender, thus limiting their therapeutic efficacy. These studies indicate that baseline levels of activation should be assessed before initiating an NKT cell based immunotherapeutic strategy.

aimThe goal of this study was to develop a sensitive method to rapidly assess NKT cell function.

methodsWe utilized artificial antigen presenting cells in combination with qPCR in order to determine NKT cell function in peripheral blood mononuclear cells from healthy donors and breast cancer patients.

resultsWe found that NKT cell activation can be detected by qPCR, but not by ELISA, in healthy donors as well as in breast cancer patients following four hour stimulation.

conclusionThis method utilizing CD1d-expressing aAPCs will enhance our knowledge of NKT cell biology and could potentially be used as a novel tool in adoptive immunotherapeutic strategies.

Indexed as

Antigen PresentationAntigens, CD1dBreast NeoplasmsFemaleHumansImmunotherapy, AdoptiveKiller Cells, NaturalNeoplasmsReal-Time Polymerase Chain ReactionAntigens, CD1daAPCsCD1dNKT cells

Identifiers

PMID24721393
PMCPMC4073584
OpenAlexW2003692122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.